AVS Bio is now a portfolio company of Arlington Capital Partners.
1 report, 1 independent
Updated Aug 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AVS Bio is now a portfolio company of Arlington Capital Partners.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Arlington Capital Partners
private equity firm focusing on leveraged buyout and recapitalization investments in middle market companies.
Nothing else this week.
Coverage
Newest first; wire copies grouped- Business WireAVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodi